Article
Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib-induced KIT mutations in gastrointestinal stromal tumours.
Molecular oncology - 1 Apr 2022
Liu Juan, Gao Jingjing, Wang Aoli, Jiang Zongru, Qi Shuang, Qi Ziping, Liu Feiyang, Yu Kailin, Cao Jiangyan, Chen Cheng, Hu Chen, Wu Hong, Wang Li, Wang Wenchao, Liu Qingsong, Liu Jing
Abstract excerpt
Drug resistance remains a major challenge in the clinical treatment of gastrointestinal stromal tumours (GISTs). While acquired on-target mutations of mast/stem cell growth factor receptor (KIT) kinase is the major resistance mechanism, activation of alternative signalling pathways may also play a role. Although several second- and third-generation KIT kinase inhibitors have been developed that could overcome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.